Harpoon Therapeutics to Present Interim Results from Phase 1 Clinical Trial of T Cell Engager HPN217 at the 64th ASH Annual Meeting and Exposition
November 03 2022 - 09:09AM
Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage
immunotherapy company developing novel T cell engagers, today
announced that it will present updated interim data from its Phase
1 clinical trial evaluating single-agent HPN217 in
relapsed/refractory multiple myeloma (RRMM) in a poster
presentation at the 64th American Society of
Hematology (ASH) Annual Meeting and Exposition being held in
person in New Orleans, Louisiana and virtually
from December 10-13, 2022. HPN217 targets B-cell maturation
antigen (BCMA) and is based on Harpoon’s proprietary Tri-specific T
cell Activating Construct (TriTAC®) platform designed to recruit a
patient’s own immune cells to kill tumor cells.
“The updated interim results from the Phase 1 trial establish
clinical proof of concept of HPN217 in heavily pretreated
relapsed/refractory multiple myeloma and provide further clinical
validation of our proprietary TriTAC T cell engager platform,” said
Julie Eastland, President and Chief Executive Officer of Harpoon
Therapeutics. “At ASH 2022, we look forward to presenting updated
clinical results from the ongoing HPN217 trial in patients with
RRMM, including additional safety, efficacy and pharmacodynamic
data from patients enrolled at higher dose levels.”
Details of the ASH poster presentation are as follows:
Abstract Title: Updated Interim Results from a
Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell
Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen
(BCMA) for Relapsed/Refractory Multiple Myeloma
(RRMM)Publication Number: 3240Session
Number/Title: Session 653 - Myeloma and Plasma Cell
Dyscrasias: Prospective Therapeutic Trials: Poster
IISession Date, Time: Sunday, December 11 from
6:00 – 8:00 p.m. CTLocation: Ernest N. Morial
Convention Center, Hall D
The poster will also be available on Harpoon’s website following
the presentation.
For more details about the ASH Annual Meeting, please visit:
https://www.hematology.org/meetings/annual-meeting
In November 2019, Harpoon Therapeutics and AbbVie announced a
licensing agreement and option to advance HPN217 and expand an
existing discovery collaboration. Under the terms of the agreement,
AbbVie may exercise its option to license HPN217 after completion
of the Phase 1/2 clinical trial.
About Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immunotherapy
company developing a novel class of T cell engagers that harness
the power of the body’s immune system to treat patients suffering
from cancer and other diseases. T cell engagers are engineered
proteins that direct a patient’s own T cells to kill target cells
that express specific proteins, or antigens, carried by the target
cells. Using its proprietary Tri-specific T cell Activating
Construct (TriTAC®) platform, Harpoon is developing a pipeline of
novel TriTACs initially focused on the treatment of solid
tumors and hematologic malignancies. Harpoon has also developed a
proprietary ProTriTAC™ platform, which applies a prodrug
concept to its TriTAC platform to create a therapeutic T cell
engager that remains inactive until it reaches the tumor. Harpoon’s
third proprietary technology platform, extended release TriTAC-XR,
is designed to mitigate cytokine release syndrome. For additional
information about Harpoon Therapeutics, please visit
www.harpoontx.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Words such as “look forward,” “will,” and similar expressions
(as well as other words or expressions referencing future events,
conditions or circumstances) are intended to identify
forward-looking statements. These forward-looking statements are
based on Harpoon Therapeutics’ expectations and assumptions as of
the date of this press release. Each of these forward-looking
statements involves risks and uncertainties that could cause
Harpoon Therapeutics’ clinical development programs, future results
or performance to differ significantly from those expressed or
implied by the forward-looking statements. Forward-looking
statements contained in this press release include, but are not
limited to, statements about the expected timing, progress, and
results of Harpoon Therapeutics’ clinical trials, the possibility
and timing of AbbVie’s option to license HPN217 and other
statements that are not historical fact. Many factors may cause
differences between current expectations and actual results,
including unexpected safety or efficacy data observed during
clinical studies, preliminary data and trends may not be predictive
of future data or results, may not demonstrate safety or
efficacy or lead to regulatory approval by the FDA or other
regulatory agencies, clinical trial site activation or enrollment
rates that are lower than expected, unanticipated or greater than
anticipated impacts or delays due to COVID-19, changes in expected
or existing competition, changes in the regulatory environment, the
uncertainties and timing of the regulatory approval process, the
timing and results of unexpected litigation or other disputes, and
the sufficiency of Harpoon Therapeutics’ cash resources. These and
other factors that may cause Harpoon Therapeutics’ actual results
to differ from those expressed or implied in the forward-looking
statements in this press release are discussed in Harpoon
Therapeutics’ filings with the U.S. Securities and Exchange
Commission, including under “Risk Factors” in Harpoon Therapeutics’
quarterly report on Form 10-Q for the quarter ended June 30,
2022, and future filings by Harpoon Therapeutics. Except
as required by law, Harpoon Therapeutics assumes no
obligation to update any forward-looking statements contained
herein to reflect any change in expectations, even as new
information becomes available.
Contacts:
Investors:ICR WestwickeRobert H. UhlManaging
Director858-356-5932 robert.uhl@westwicke.com
Media:uncapped communications862-368-4464media@harpoontx.com
Harpoon Therapeutics (NASDAQ:HARP)
Historical Stock Chart
From Feb 2024 to Mar 2024
Harpoon Therapeutics (NASDAQ:HARP)
Historical Stock Chart
From Mar 2023 to Mar 2024